Imatinib Metabolism and Disposition in Isolated Rat Perfused Liver Imatinib Metabolism and Disposition in Isolated Rat Perfused Liver
Iranian Journal of Pharmaceutical Sciences,
Vol. 12 No. 1 (2016),
15 January 2016
,
Page 69-84
https://doi.org/10.22037/ijps.v12.40792
Abstract
Imatinib is an orally administered tyrosine kinase inhibitor which inhibits the Bcr-Abl protein-tyrosine kinase with high selectivity. Imatinib is rapidly absorbed from the gut, after oral intake and has an almost absolute bioavailability of 98%. The metabolism of imatinib is mediated by the cytochrome P450 (CYP) isoenzymes in the liver and gut wall. CGP74588 is a major active metabolite of imatinib. The study was performed on Male Sprague-Dawley rats (250-300 g) housing under artificial light on a 12-h light/dark cycle with free access to standard laboratory chow and water. Re-circulating (at imatinib concentration of 1 and 5 μg/ml) and single-pass (imatinib dose of 1mg) perfusion modes in the presence and absence of BSA were tested. Throughout the experiment, perfusate temperature (37± 0.5 C°), pH (7.4±0.2) and liver viability (ALT and AST) were monitored. The concentrations of imatinib and its main metabolite in perfusion buffer and liver homogenate were determined by a validated HPLC method.No metabolite was detected in outlet perfusate in all conditions. However, negligible amounts of metabolite were found in liver homogenate at 1 and 5 μg/ml imatinib concentrations in re-circulating perfusion mode. The rapid and remarkable disappearance of imatinib from perfusate was related to its accumulation in liver. Statistical moment definition was used to calculate some pharmacokinetic parameters. These calculations also confirmed liver accumulation and slow and sustained dissociation of imatinib from liver.
- HPLC
- Imatinib
- Isolated rat liver
- Metabolism
- Pharmacokinetic
How to Cite
References
[2] Druker BJ, Lydon NB. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest. 2000; 105: 3-7.
[3] Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood. 2000; 96: 3343-3356.
[4] Druker BJ, Guilhot F, O'Brien SG., et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006; 355: 2408-2417.
[5] Capdeville R, Buchdunger E, Zimmermann J, Matter A. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov. 2002; 1: 493-502.
[6] de Kogel CE, Schellens JH. Imatinib. Oncologist. 2007; 12: 1390-1394.
[7] Peng B, Lloyd P, Schran H. Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005; 44: 879-894.
[8] Cohen MH, Williams G, Johnson JR, Duan J, Gobburu J, Rahman A, Benson K, Leighton J, Kim SK, Wood R, Rothmann M, Chen G, U KM, Staten AM, Pazdur R. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin Cancer Res. 2002; 8: 935-942.
[9] Ma S, Xu Y, Shou M. Characterization of imatinib metabolites in rat and human liver microsomes: differentiation of hydroxylation from N-oxidation by liquid chromatography/atmospheric pressure chemical ionization mass spectrometry. Rapid Commun Mass Spectrom. 2009; 23: 1446-1450.
[10] Golabchifar AA, Rouini M-R, Shafaghi B, Rezaee S, Forouadi A, Khoshayand M-R. Optimization of simultaneous determination of imatinib and its major metabolite (CGP74588) in human plasma by a rapid HPLC method using D-optimal experimental design. Submitted to J Chromatogr B Analyt Technol Biomed Life Sci.
[11] Kakutani T, Yamaoka K, Hashida M, Sezaki H. A new method for assessment of drug disposition in muscle: application of statistical moment theory to local perfusion systems. J Pharmacokinet Biopharm. 1985; 13: 609-631.
[12] Mehvar R, Chimalakonda AP. Hepatic disposition of cyclosporine A in isolated perfused rat livers. J Pharm Pharm Sci. 2004 17; 7(1):47-54.
[13] Rouini MR, Ghazi-Khansari M, Ardakani YH, Dasian Z, Lavasani H. A disposition kinetic study of tramadol in rat perfused liver. Biopharm Drug Dispos. 2008 May; 29:231-235.
[14] Senior K. Gleevec does not cross blood-brain barrier. Lancet Oncol. 2003; 4: 198.
[15] Dai H, Marbach P, Lemaire M, Hayes M, Elmquist WF. Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux. J Pharmacol Exp Ther. 2003; 304: 1085-1092.
[16] Burger H, van Tol H, Brok M, Wiemer EA, de Bruijn EA, Guetens G, de Boeck G, Sparreboom A, Verweij J, Nooter K. Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps. Cancer Biol Ther. 2005; 4: 747-752.
[17] Van LM, Swales J, Hammond C, Wilson C, Hargreaves JA, Rostami-Hodjegan A. Kinetics of the time-dependent inactivation of CYP2D6 in cryopreserved human hepatocytes by ethylenedioxymethamphetamine (MDMA). Eur J Pharm Sci. 2007; 31: 53-61.
- Abstract Viewed: 300 times
- IJPS_Volume 12_Issue 1_Pages 69-84 Downloaded: 195 times